Document Detail

Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial.
MedLine Citation:
PMID:  23318311     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: D-Dimer testing is sensitive but not specific for diagnosing deep venous thrombosis (DVT). Changing the use of testing and the threshold level for a positive test result on the basis of risk for DVT might improve the tradeoff between sensitivity and specificity and reduce the need for testing.
OBJECTIVE: To determine whether using a selective D-dimer testing strategy based on clinical pretest probability (C-PTP) for DVT is safe and reduces diagnostic testing compared with using a single D-dimer threshold for all patients.
DESIGN: Randomized, multicenter, controlled trial. Patients were allocated using a central automated system. Ultrasonographers and study adjudicators but not other study personnel were blinded to trial allocation. ( NCT00157677)
SETTING: 5 Canadian hospitals.
PATIENTS: Consecutive symptomatic patients with a first episode of suspected DVT.
INTERVENTION: Selective testing (n = 860), defined as D-dimer testing for outpatients with low or moderate C-PTP (DVT excluded at D-dimer levels <1.0 µg/mL [low C-PTP] or <0.5 µg/mL [moderate C-PTP]) and venous ultrasonography without D-dimer testing for outpatients with high C-PTP and inpatients, or uniform testing (n = 863), defined as D-dimer testing for all participants (DVT excluded at D-dimer levels <0.5 µg/mL).
MEASUREMENTS: The proportion of patients not diagnosed with DVT during initial testing who had symptomatic venous thromboembolism during 3-month follow-up and the proportion of patients undergoing D-dimer testing and ultrasonography.
RESULTS: The incidence of symptomatic venous thromboembolism at 3 months was 0.5% in both study groups (difference, 0.0 percentage point [95% CI, -0.8 to 0.8 percentage points]). Selective testing reduced the proportion of patients who required D-dimer testing by 21.8 percentage points (CI, 19.1 to 24.8 percentage points). It reduced the proportion who required ultrasonography by 7.6 percentage points (CI, 2.9 to 12.2 percentage points) overall and by 21.0 percentage points (CI, 14.2 to 27.6 percentage points) in outpatients with low C-PTP.
LIMITATION: Results may not be generalizable to all D-dimer assays or patients with previous DVT, study personnel were not blinded, and the trial was stopped prematurely.
CONCLUSION: A selective D-dimer testing strategy seems as safe as and more efficient than having everyone undergo D-dimer testing when diagnosing a first episode of suspected DVT.
PRIMARY FUNDING SOURCE: Heart and Stroke Foundation of Ontario.
Lori-Ann Linkins; Shannon M Bates; Eddy Lang; Susan R Kahn; James D Douketis; Jim Julian; Sameer Parpia; Peter Gross; Jeffrey I Weitz; Frederick A Spencer; Agnes Y Y Lee; Martin J O'Donnell; Mark A Crowther; Howard H Chan; Wendy Lim; Sam Schulman; Jeffrey S Ginsberg; Clive Kearon
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of internal medicine     Volume:  158     ISSN:  1539-3704     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-15     Completed Date:  2013-03-11     Revised Date:  2013-07-23    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  93-100     Citation Subset:  AIM; IM    
McMaster University, Hamilton, Ontario, Canada.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fibrin Fibrinogen Degradation Products / analysis*
Follow-Up Studies
Sensitivity and Specificity
Venous Thromboembolism / blood,  diagnosis*,  ultrasonography
Venous Thrombosis / blood,  diagnosis*,  ultrasonography
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/fibrin fragment D
Comment In:
Biomark Med. 2013 Jun;7(3):400-1
Nat Rev Cardiol. 2013 Mar;10(3):118   [PMID:  23380976 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in t...
Next Document:  Online professionalism investigations by state medical boards: first, do no harm.